Clinical trial
AVANDIA With Glyburide In African American And Hispanic Patients With Type 2…
NCT00333723 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00333723 |
|---|---|
| Title | AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone |
| Official title | A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg Once Daily) in Combination With Glyburide in African American and Hispanic Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Glyburide Monotherapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Rosiglitazone |
| Enrollment | 245 |
| Start date | Jul 28, 2000 |
| Primary completion | Jan 6, 2003 |
| Completion | Jan 6, 2003 |
| First posted | Jun 6, 2006 |
| Last update posted | Oct 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: